Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
PaperCitations, authors & open-access status
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 218 citations, 2022 year and hybrid oa status.
218
Citations
2022
Year
hybrid
OA Status